Alpha 2.0
Login Register
» Articles » PMID: 30970161

Real-World Data for Regulatory Decision Making: Challenges and Possible Solutions for Europe

Overview
Journal Clin Pharmacol Ther
Publisher Wiley
Specialty Pharmacology
Date 2019 Apr 11
PMID 30970161
Citations 108
Authors
Alison Cave
Xavier Kurz
Peter Arlett
Affiliations
Soon will be listed here.
Citing Articles

Real-World Data and Real-World Evidence in Regulatory Decision Making: Report Summary From the Council for International Organizations of Medical Sciences (CIOMS) Working Group XIII.

Hennessy S, Atsuta Y, Hill S, Rago L, Juhaeri J Pharmacoepidemiol Drug Saf. 2025; 34(3):e70117.

PMID: 40070104 PMC: 11897686. DOI: 10.1002/pds.70117.

The EU project Real4Reg: unlocking real-world data with AI.

Peltner J, Becker C, Wicherski J, Wortberg S, Aborageh M, Costa I Health Res Policy Syst. 2025; 23(1):27.

PMID: 40016823 PMC: 11869640. DOI: 10.1186/s12961-025-01287-y.

Stakeholders' Perspectives Toward the Use of Patient Registry Data for Decision-Making on Medicines: A Cross-Sectional Survey.

Windfuhr F, de Vries S, Melinder M, Dahlqvist T, Almeida D, Sepodes B Drug Saf. 2025; .

PMID: 39987538 DOI: 10.1007/s40264-025-01528-7.

Effect of Multimodal App-Based Interventions on Glycemic Control in Patients With Type 2 Diabetes: Systematic Review and Meta-Analysis.

Bodner E, Roth L, Wiencke K, Bischoff C, Schwarz P J Med Internet Res. 2025; 27:e54324.

PMID: 39854703 PMC: 11806272. DOI: 10.2196/54324.

Multiple Perspectives on the Need for Real-World Evidence to Inform Regulatory and Health Technology Assessment Decision-Making: Scoping Review and Stakeholder Interviews.

Jansen M, Dekkers O, le Cessie S, Hooft L, Gardarsdottir H, de Boer A Pharmacoepidemiol Drug Saf. 2025; 34(1):e70074.

PMID: 39777765 PMC: 11706668. DOI: 10.1002/pds.70074.

References
1.
Klungel O, Kurz X, de Groot M, Schlienger R, Tcherny-Lessenot S, Grimaldi L . Multi-centre, multi-database studies with common protocols: lessons learnt from the IMI PROTECT project. Pharmacoepidemiol Drug Saf. 2016; 25 Suppl 1:156-65. DOI: 10.1002/pds.3968. View
2.
Sterne J, Hernan M, Reeves B, Savovic J, Berkman N, Viswanathan M . ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016; 355:i4919. PMC: 5062054. DOI: 10.1136/bmj.i4919. View
3.
Collier S, Harvey C, Brewster J, Bakerly N, Elkhenini H, Stanciu R . Monitoring safety in a phase III real-world effectiveness trial: use of novel methodology in the Salford Lung Study. Pharmacoepidemiol Drug Saf. 2016; 26(3):344-352. PMC: 5347861. DOI: 10.1002/pds.4118. View
4.
Santoro A, Genov G, Spooner A, Raine J, Arlett P . Promoting and Protecting Public Health: How the European Union Pharmacovigilance System Works. Drug Saf. 2017; 40(10):855-869. PMC: 5606958. DOI: 10.1007/s40264-017-0572-8. View
5.
Wang S, Schneeweiss S, Berger M, Brown J, de Vries F, Douglas I . Reporting to Improve Reproducibility and Facilitate Validity Assessment for Healthcare Database Studies V1.0. Pharmacoepidemiol Drug Saf. 2017; 26(9):1018-1032. PMC: 5639362. DOI: 10.1002/pds.4295. View